细胞外基质在胰腺癌中的作用机制及治疗靶点研究进展

doi:10.11904/j.issn.1002-3070.2025.06.011

摘要/Abstract

摘要： 胰腺癌是一种预后极差的消化道恶性肿瘤,具有高度侵袭性与耐药性,患者5年生存率约为10%。目前,手术切除、化疗和放疗是其标准治疗方法。然而这些方法仍存在诸多局限,极易出现肿瘤复发及耐药问题。因此,探寻新的治疗靶点已成为当前研究的迫切需求。细胞外基质作为肿瘤微环境的关键组成部分,在胰腺癌进展及耐药中发挥着重要作用。近年研究表明,靶向干预细胞外基质有望为胰腺癌治疗带来新的突破。本文基于国内外最新研究进展,系统综述了细胞外基质作为胰腺癌治疗靶点的理论依据。

关键词: 胰腺癌, 细胞外基质, 肿瘤微环境, 肿瘤耐药, 靶向治疗

Abstract: Pancreatic cancer is a malignant tumor of digestive tract with an extremely poor prognosis.It is highly invasiveness and drug resistance.The 5-year survival rate of patients is only approximately 10%.Currently,Surgical resection,chemotherapy,and radiotherapy are the standard treatment methods,but there are still many limitations and are prone to tumor recurrence and drug resistance.Therefore,exploring new therapeutic targets has become an urgent need in current research.As a key component of tumor microenvironment,the extracellular matrix plays an important role in the progression and drug resistance of pancreatic cancer.Recent studies have shown that targeted intervention of the extracellular matrix is expected to bring new breakthroughs in the treatment of pancreatic cancer.Based on the latest research progress at domestically and abroad,this paper systematically reviews the theoretical basis of extracellular matrix as a therapeutic target for pancreatic cancer.

Key words: pancreatic cancer, extracellular matrix, tumor microenvironment, tumor resistance, targeted therapy

中图分类号:

R735.9

赵志龙, 侯俊明. 细胞外基质在胰腺癌中的作用机制及治疗靶点研究进展[J]. 实用肿瘤学杂志, 2025, 39(6): 535-541.

ZHAO Zhilong, HOU Junming. Research progress on the mechanism and therapeutic targets of extracellular matrix in pancreatic cancer[J]. Journal of Practical Oncology, 2025, 39(6): 535-541.

参考文献

1 Chakraborty A,Halder B,Mondal S,et al.NADPH oxidase 1 in chronic pancreatitis-activated pancreatic stellate cells facilitates the progression of pancreatic cancer[J].Am J Cancer Res,2023,13(1):118-142.
2 Li BQ,Liu XY,Mao T,et al.The research progress of anti-inflammatory and anti-fibrosis treatment of chronic pancreatitis[J].Front Oncol,2022,12:1050274.
3 Munigala S,Almaskeen S,Subramaniam DS,et al.Acute pancreatitis recurrences augment long-term pancreatic cancer risk[J].Am J Gastroenterol,2023,118(4):727-737.
4 Liu Z,Hiromitsu H,Kazuki M,et al.Biological and clinical impacts of glucose metabolism in pancreatic ductal adenocarcinoma[J].Cancers(Basel),2023,15(2):498.
5 Popovic K,Smolović B,Martinović M,et al.The relationship between diabetes mellitus and pancreatic cancer-diabetes mellitus as a red flag for pancreatic cancer[J].Cancer Epidemiol Biomarkers Prev,2023,32(3):298-305.
6 Ruze R,Chen Y,Xu R,et al.Obesity,diabetes mellitus,and pancreatic carcinogenesis:correlations,prevention,and diagnostic implications[J].Biochim Biophys Acta Rev Cancer,2023,1878(1):188844.
7 Waleleng BJ,Adiwinata R,Wenas NT,et al.Screening of pancreatic cancer:target population,optimal timing and how[J]? Ann Med Surg(Lond),2022,84:104814.
8 胰腺癌诊疗指南(2022年版)[J].中华消化外科杂志,2022,21(9):1117-1136.
9 Cronin KA,Scott S,Firth AU,et al.Annual report to the nation on the status of cancer,part 1:national cancer statistics[J].Cancer,2022,128(24):4251-4284.
10 Xiang H,Yang R,Tu J,et al.Metabolic reprogramming of immune cells in pancreatic cancer progression[J].Biomed Pharmacother,2023,157:113992.
11 Kim J.Cell dissemination in pancreatic cancer[J].Cells,2022,11(22):3683.
12 Koustas E,Trifylli EM,Sarantis P,et al.The emerging role of microRNAs and autophagy mechanism in pancreatic cancer progression:future therapeutic approaches[J].Genes(Basel),2022,13(10):1868.
13 Tiwari A,Trivedi R,Lin SY.Tumor microenvironment:barrier or opportunity towards effective cancer therapy[J].J Biomed Sci,2022,29(1):83.
14 Jiang J,Mei J,Yi S,et al.Tumor associated macrophage and microbe:the potential targets of tumor vaccine delivery[J].Adv Drug Deliv Rev,2022,180:114046.
15 Singh M,Pal P,Dutta RS,et al.Nanodiamond mediated molecular targeting in pancreatic ductal adenocarcinoma:disrupting the tumor-stromal cross-talk,next hope on the horizon?[J].Curr Cancer Drug Targets,2023,23(8):620-633.
16 Yuan Z,Li Y,Zhang S,et al.Extracellular matrix remodeling in tumor progression and immune escape:from mechanisms to treatments[J].Mol Cancer,2023,22(1):48.
17 Peiffer R,Boumahd Y,Gullo C,et al.Cancer-associated fibroblast diversity shapes tumor metabolism in pancreatic cancer[J].Cancers(Basel),2022,15(1):61.
18 Ge W,Yue M,Wang Y,et al.A novel molecular signature of cancer-associated fibroblasts predicts prognosis and immunotherapy response in pancreatic cancer[J].Int J Mol Sci,2022,24(1):156.
19 Bryce AS,Dreyer SB,Froeling FEM,et al.Exploring the biology of cancer-associated fibroblasts in pancreatic cancer[J].Cancers(Basel),2022,14(21):5302.
20 Shinkawa T,Ohuchida K,Nakamura M.Heterogeneity of cancer-associated fibroblasts and the tumor immune microenvironment in pancreatic cancer[J].Cancers(Basel),2022,14(16):3994.
21 Yang XY,Zhang JG,Zhou QM,et al.Extracellular matrix modulating enzyme functionalized biomimetic Au nanoplatform-mediated enhanced tumor penetration and synergistic antitumor therapy for pancreatic cancer[J].J Nanobiotechnology,2022,20(1):524.
22 Liu X,Iovanna J,Santofimia-Castaño P.Stroma-targeting strategies in pancreatic cancer:a double-edged sword[J].J Physiol Biochem,2023,79(1):213-222.
23 Papalazarou V,Drew J,Juin A,et al.Collagen VI expression is negatively mechanosensitive in pancreatic cancer cells and supports the metastatic niche[J].J Cell Sci,2022,135(24):jcs259978.
24 Madsen EA,Thorlacius-Ussing J,Nissen NI,et al.Type XXII collagen complements fibrillar collagens in the serological assessment of tumor fibrosis and the outcome in pancreatic cancer[J].Cells,2022,11(23):3763.
25 Ko S,Jung KH,Yoon YC,et al.A novel DDR1 inhibitor enhances the anticancer activity of gemcitabine in pancreatic cancer[J].Am J Cancer Res,2022,12(9):4326-4342.
26 Ding C,Yu Z,Liu X,et al.Collagen type VII α1 chain:a promising prognostic and immune infiltration biomarker of pancreatic cancer[J].Oncol Lett,2023,25(2):77.
27 Jørgensen C.Untangling the tumorigenic role of homotrimeric collagen I[J].Cancer Cell,2022,40(8):802-804.
28 Chen Y,Yang S,Tavormina J,et al.Oncogenic collagen I homotrimers from cancer cells bind to α3β1 integrin and impact tumor microbiome and immunity to promote pancreatic cancer[J].Cancer Cell,2022,40(8):818-834.e9.
29 Jiang C,Wang M,Yao W,et al.Comprehensive analysis on prognosis and immune infiltration of lysyl oxidase family members in pancreatic adenocarcinoma with experimental verification[J].Front Mol Biosci,2022,9:778857.
30 Coffelt SB,Morton JP.LOXL2 in pancreatic tumourigenesis:the complexity of tumour-stromal crosstalk exemplified[J].Gut,2023,72(2):221-222.
31 Alonso-Nocelo M,Ruiz-Cañas L,Sancho P,et al.Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma[J].Gut,2023,72(2):345-359.
32 Minici C,Rigamonti E,Lanzillotta M,et al.B lymphocytes contribute to stromal reaction in pancreatic ductal adenocarcinoma[J].Oncoimmunology,2020,9(1):1794359.
33 Murphy JE,Wo JY,Ryan DP,et al.Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer:a phase 2 clinical trial[J].JAMA Oncol,2019,5(7):1020-1027.
34 Reis JSD,Santos MARDC,da Costa KM,et al.Increased expression of the pathological O-glycosylated form of oncofetal fibronectin in the multidrug resistance phenotype of cancer cells[J].Matrix Biol,2023,118:47-68.
35 Sato N,Kohi S,Hirata K,et al.Role of hyaluronan in pancreatic cancer biology and therapy:once again in the spotlight[J].Cancer Sci,2016,107(5):569-575.
36 Kobayashi T,Chanmee T,Itano N,et al.Hyaluronan:metabolism and function[J].Biomolecules,2020,10(11):1525.
37 Jiang Y,Zhang H,Wang J,et al.Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy[J].J Hematol Oncol,2022,15(1):34.
38 Caon I,Bartolini B,Parnigoni A,et al.Revisiting the hallmarks of cancer:the role of hyaluronan[J].Semin Cancer Biol,2020,62:9-19.
39 Nakano M,Taguchi R,Kikushige Y,et al.RHAMM marks proliferative subpopulation of human colorectal cancer stem cells[J].Cancer Sci,2023,114(7):2895-2906.
40 Markowska A,Antoszczak M,Markowska J,et al.CEMIP-mediated hyaluronan metabolism facilitates SCLC metastasis by activating TLR2/c-Src/ERK1/2 axis[J].Biochim Biophys Acta Mol Cell Res,2023,1870(5):119451.
41 Maksym A,Mielczarek-Palacz A,Mika J,et al.Role of hyaluronic acid in selected malignant neoplasms in women[J].Biomedicines,2023,11(2):304.
42 Yang YM,Noureddin M,Liu C,et al.Hyaluronan synthase 2-mediated hyaluronan production mediates Notch1 activation and liver fibrosis[J].Sci Transl Med,2019,11(496):eaat9284.
43 Wiedmann L,De Angelis Rigotti F,Vaquero-Siguero N,et al.HAPLN1 potentiates peritoneal metastasis in pancreatic cancer[J].Nat Commun,2023,14(1):2353.
44 Van Cutsem E,Tempero MA,Sigal D,et al.Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma[J].J Clin Oncol,2020,38(27):3185-3194.
45 Ko AH,Kim KP,Siveke JT,et al.Atezolizumab plus PEGPH20 versus chemotherapy in advanced pancreatic ductal adenocarcinoma and gastric cancer:MORPHEUS phase Ib/II umbrella randomized study platform[J].Oncologist,2023,28(6):553-e472.
46 Qin W,Zhang J,Rong R,et al.Osteoglycin(OGN)promotes tumorigenesis of pancreatic cancer cell via targeting ID4[J].Tissue Cell,2022,78:101867.
47 Hurtado de Mendoza T,Mose ES,Botta GP,et al.Tumor-penetrating therapy for β5 integrin-rich pancreas cancer[J].Nat Commun,2021,12(1):1541.
48 Su L,Chen Y,Huang C,et al.Targeting Src reactivates pyroptosis to reverse chemoresistance in lung and pancreatic cancer models[J].Sci Transl Med,2023,15(678):eabl7895.
49 Yu P,Zhang X,Liu N,et al.Pyroptosis:mechanisms and diseases[J].Signal Transduct Target Ther,2021,6(1):128.
50 Cheng C,Liu D,Liu Z,et al.Positive feedback regulation of lncRNA TPT1-AS1 and ITGB3 promotes cell growth and metastasis in pancreatic cancer[J].Cancer Sci,2022,113(9):2986-3001.
51 Malsy M,Hofer V,Schmidbauer S,et al.Effects of ketamine,S-ketamine and MK 801 on integrin beta-3-mediated cell migration in pancreatic carcinoma[J].J Cancer Sci Clin Ther,2022,6(4):446-451.
52 Rapetti-Mauss R,Nigri J,Berenguier C,et al.SK2 channels set a signalling hub bolstering CAF-triggered tumourigenic processes in pancreatic cancer[J].Gut,2023,72(4):722-735.
53 Gregori A,Bergonzini C,Capula M,et al.Prognostic significance of integrin subunit alpha 2(ITGA2)and role of mechanical cues in resistance to gemcitabine in pancreatic ductal adenocarcinoma(PDAC)[J].Cancers(Basel),2023,15(3):628.
54 Wu C,Rakhshandehroo T,Wettersten HI,et al.Pancreatic cancer cells upregulate LPAR4 in response to isolation stress to promote an ECM-enriched niche and support tumour initiation[J].Nat Cell Biol,2023,25(2):309-322.
55 Tomas Bort E,Joseph MD,Wang Q,et al.Purinergic GPCR-integrin interactions drive pancreatic cancer cell invasion[J].Elife,2023,12:e86971.
56 Wang Y,Wang S,Liu M,et al.The function of NAT10-driven N4-acetylcytidine modification in cancer:novel insights and potential therapeutic targets[J].Cell Biosci,2025,15(1):165.
57 Mortensen REJ,Holmström MO,Lisle TL,et al.Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy[J].J Immunother Cancer,2023,11(3):e006432.
58 Liu H,Chen B,Zardi L,et al.Soluble fibronectin promotes migration of oral squamous-cell carcinoma cells[J].Int J Cancer,1998,78(2):261-267.
59 Liu Y,Sinjab A,Min J,et al.Conserved spatial subtypes and cellular neighborhoods of cancer-associated fibroblasts revealed by single-cell spatial multi-omics[J].Cancer Cell,2025,43(5):905-924.e6.
60 Zhang L,Liu C,Gao H,et al.Study on the expression profile and role of decorin in the progression of pancreatic cancer[J].Aging(Albany NY),2021,13(11):14989-14998.
61 Li H,Chiang CL,Kwak KJ,et al.Extracellular vesicular analysis of glypican 1 mRNA and protein for pancreatic cancer diagnosis and prognosis[J].Adv Sci(Weinh),2024,11(11):e2306373.

[1]	蔡医擎, 代恩勇. 胃癌分子靶向治疗的研究进展[J]. 实用肿瘤学杂志, 2025, 39(6): 542-550.
[2]	辛鑫, 熊文婧, 张春暖, 李晓静, 高雪, 张悦. 乳酸化修饰:癌症治疗中的新兴靶点[J]. 实用肿瘤学杂志, 2025, 39(5): 433-436.
[3]	李冬生, 李泽昊, 陈永刚. 铁死亡相关基因的DNA甲基化风险评分模型在结肠癌预后与免疫特征评估中的应用[J]. 实用肿瘤学杂志, 2025, 39(3): 224-234.
[4]	叶倩妮, 李娟, 王发琳, 刘家仁. 植物化学物在肿瘤微环境中的作用研究进展[J]. 实用肿瘤学杂志, 2025, 39(3): 245-250.
[5]	武旭, 德乐黑巴特尔, 达林泰, 苏尼特, 刘军. 长链非编码RNA在口腔鳞状细胞癌中的研究进展[J]. 实用肿瘤学杂志, 2025, 39(3): 251-255.
[6]	邵禹铭, 朱坤兵, 张洁. SP/NK-1R系统在乳腺癌中的研究进展[J]. 实用肿瘤学杂志, 2024, 38(4): 268-272.
[7]	黑龙江省医学会乳腺肿瘤学组. 黑龙江省乳腺癌HER2低表达临床病理诊断专家共识(2024版)[J]. 实用肿瘤学杂志, 2024, 38(2): 71-78.
[8]	樊婷婷, 丁丹妮, 赵子雪, 于洋, 韩凤娟. 脂肪酸代谢与卵巢癌[J]. 实用肿瘤学杂志, 2023, 37(5): 429-433.
[9]	罗汀繁, 孙鹏飞. 巨噬细胞/小胶质细胞在胶质瘤微环境中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(5): 443-448.
[10]	曹莹月, 庞露薏, 张键, 金时. 癌相关成纤维细胞在非小细胞肺癌进展中的作用[J]. 实用肿瘤学杂志, 2023, 37(4): 383-388.
[11]	徐婷, 程华, 张维. 老年胰腺癌早期诊断及微创外科治疗的研究进展[J]. 实用肿瘤学杂志, 2023, 37(3): 257-261.
[12]	伦立鑫, 钟振滨, 赵新宇, 吴筹, 郝春成. 抗EGFR治疗在头颈部鳞癌中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(3): 276-280.
[13]	刘欣欣, 马西元, 缪美琪, 王语晴, 陈晶. IL-6及其受体在乳腺癌治疗中的作用研究进展[J]. 实用肿瘤学杂志, 2023, 37(2): 149-154.
[14]	王嘉倍, 张运广, 刘连新. 免疫治疗联合分子靶向药物治疗中晚期肝细胞癌的临床疗效及安全性分析:一项单臂回顾性研究[J]. 实用肿瘤学杂志, 2022, 36(6): 489-494.
[15]	张淑敏, 张弓. ILC2s在肿瘤免疫调控中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(6): 566-569.